Chicago's Pope Leo celebration sold out quickly — drawing second market frenzy
CHICAGO - Tickets for the Chicago Archdiocese's celebration of Pope Leo XIV at Rate Field on June 14 sold out quickly on Friday, sparking a surge in resales on the secondary market.
The Brief
Tickets for the Chicago Archdiocese's celebration of Pope Leo XIV at Rate Field on June 14 sold out quickly on Friday.
Hundreds of tickets purchased for $5 were being resold on sites like StubHub for hundreds of dollars or more.
The event will feature a video presentation about the Pope's Chicago roots, speakers from Cardinal Robert Prevost's time in the city, and a recorded greeting from the Pope himself.
What we know
Tickets went on sale at 10 a.m. for $5 each, and by mid-afternoon only upper deck seats remained. By 10 p.m. on Friday, all tickets available on Ticketmaster were sold out.
"We sold over 10,000 tickets in the first half hour," said Chicago White Sox senior vice president Christine O'Reilly. "I think it's amazing, and it goes to show that the Pope is a pope for all people and people want to be part of this."
The event, produced by the Archdiocese of Chicago, will feature a video presentation about the Pope's Chicago roots, speakers from Cardinal Robert Prevost's time in the city, and a recorded greeting from the Pope himself.
"What it is going to be is an insight into who the Holy Father is," said Archdiocese Vicar General Bishop Larry Sullivan. "It's a way for us to really learn about his South Side roots, to learn about him, and for us to be able to relate to him."
Sullivan noted that Rate Field was chosen as the venue because the Pope is a lifelong White Sox fan and attended the 2005 World Series.
What's next
As for logistics, O'Reilly said all the buzz about the event means the show must go on.
"We're making plans. Obviously, it's two weeks away, so we've got our work cut out for us. The altar will be set up on a stage on the field, with some seating on the field and in the stands. We're going to open the gates at 12:30 that day."
Meanwhile, hundreds of tickets purchased for $5 were being resold on sites like StubHub for hundreds of dollars or more.
"I think that's telling us that there's a great buzz, that this is a historic moment and people want to be part of something special," Sullivan said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
These biotech companies have several catalysts ahead -- and in the past have soared on good news. They both offer innovative candidates that could result in game-changing treatments for patients. 10 stocks we like better than Viking Therapeutics › If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line. As an investor in these companies, you can benefit as they report positive clinical trial news, score a regulatory approval, or start generating product revenue. Wall Street considers two candidates extremely compelling right now, with forecasts for potential gains of more than 80% and 200% in the coming 12 months. One of these players is working in the high-growth area of weight loss drugs, and the other candidate showed its strengths by winning the world's first-ever approval of a product based on CRISPR gene editing. Let's check out these two biotech stocks to buy before they skyrocket. Viking Therapeutics (NASDAQ: VKTX) soared early last year when it reported strong data from the phase 2 trial of its weight loss candidate, VK2735, but the stock has since given back those gains and is trading closer to the level it was at prior to that data announcement. Since, the company has continued to advance VK2735 in injectable form and a version in pill form, and demand for these sorts of drugs remains high -- these are two reasons to believe that Viking has the potential to take off again. And catalysts may be on the horizon. The drug works in a manner similar to Eli Lilly's blockbuster tirzepatide, sold under the names Mounjaro and Zepbound. These drugs interact with hormones involved in digestion and have helped people quickly and safely lose weight. Viking is beginning the phase 3 trial for injectable VK2735 in the second quarter and expects data from its phase 2 trial of the pill version in the second half. Any data announcements could result in big moves for the stock, as there is plenty of room for a new company to enter the weight loss drug market -- one forecast to approach $100 billion in a few years. Wall Street is optimistic about Viking's prospects, with the average price forecast predicting an increase of about 240% in the stock price from today's level. Of course, Viking depends heavily on the outcome of these trials, so some risk is involved -- but data have been strong, so growth investors may want to get in on Viking now to potentially post a big win later. CRISPR Therapeutics (NASDAQ: CRSP) stock surged in the year leading up to a major milestone: its first product approval. But since last year's launch of Casgevy, a gene-editing treatment for blood disorders, the stock has been on the decline. Sometimes, investors buy a stock well before the company wins approval or launches a product, then lock in gains after the good news lands -- and I think this is what's happened here. But what this does is offer us a chance to get in at a very good price on a promising company that could deliver fantastic news down the road. Casgevy, as a gene-editing treatment, requires a longer time to roll out than a pill or injection, as it includes several steps that happen over a period of months. The company recently said new patient initiations should increase "significantly" this year -- so there's reason to be optimistic about revenue growth ahead. CRISPR Therapeutics also recently reported positive phase 1 data for a gene editing candidate addressing the problem of high cholesterol. And the company expects to report data soon from a phase 1 trial of a candidate targeting patients with elevated levels of lipoprotein(a) -- a risk factor for cardiovascular events. These could represent huge markets for CRISPR Therapeutics if the candidates reach the finish line, and in the meantime, any potential positive news could boost the stock. The company also expects other trial updates in candidates for oncology and autoimmune diseases this year -- so this biotech's calendar is full of possible catalysts. Wall Street's average price forecast calls for an 84% gain for CRISPR Therapeutics from today's price -- if all goes well in clinical trials and Casgevy starts to show revenue growth, now could represent a golden buying opportunity for growth investors. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. 2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
42 minutes ago
- Yahoo
Dan Ives Says Market Is 'Massively Underestimating' This AI Play, Urges Investors To Look Beyong Mag 7
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Dan Ives' new artificial intelligence exchange-traded fund (ETF) holds securities beyond the Magnificent 7 stocks, as he believes in looking past valuations for investments in the technology sector. What Happened: The Dan IVES Wedbush AI Revolution ETF (NYSE:IVES), managed by the Wedbush analyst, started trading on June 4, earlier this month. Ives boasts of the fund by saying that it just doesn't have the top four, five Magnificent 7 names, but stocks which investors wouldn't even thematically consider as an AI name today. "I believe the market is still massively underestimating what the growth is going to look like for the AI revolution in tech," he told CNBC. Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — According to him, tech trade remains significant even for the investors who missed out on its growth in the past few years. "If you focus just on valuation, you miss every transformational tech stock of the last 20 years," Ives said. Ives says Oracle Corp. (NYSE:ORCL) will be the 'epicenter' of the AI theme, while highlighting other 'AI 30' stocks which are part of his fund. Palantir Technologies Inc. (NASDAQ:PLTR), International Business Machines Corp. (NYSE:IBM), Salesforce Inc. (NYSE:CRM), SoundHound AI Inc. (NASDAQ:SOUN), and Innodata Inc. (NASDAQ:INOD) are a few notable names that are a part of his ETF's 'AI 30' basket. Microsoft Corp. (NASDAQ:MSFT), Nvidia Corp. (NASDAQ:NVDA), and Broadcom Inc. (NASDAQ:AVGO) are the top three holdings of the IVES It Matters: The 'AI 30' stocks, which are a part of the IVES ETF, hold the AI plays from multiple industries. They include hyperscalers, cybersecurity, consumer platforms, and robotics. According to Ives, the list was compiled from his deep dives into major AI players. The ETF has $183 million in assets under management as of June 17 close. Ives said that the AI space was experiencing a "golden age." The Dan IVES Wedbush AI Revolution ETF has risen by 2.76% since its inception. A comparable index, S&P Kensho Global Artificial Intelligence Enablers, rose 6.08% on a month-to-date basis. Meanwhile, the SPDR S&P 500 ETF Trust (NYSE:SPY) and Invesco QQQ Trust ETF (NASDAQ:QQQ), which track the S&P 500 index and Nasdaq 100 index, respectively, declined slightly on Wednesday. The SPY was down 0.015% at $597.44, while the QQQ was 0.017% lower at $528.99, according to Benzinga Pro data. Read Next: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. Back a bold new approach to cancer treatment with high-growth potential. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? Photo courtesy: Shutterstock This article Dan Ives Says Market Is 'Massively Underestimating' This AI Play, Urges Investors To Look Beyong Mag 7 originally appeared on
Yahoo
42 minutes ago
- Yahoo
PGA Tour Sends Strong Scottie Scheffler Message on Saturday
PGA Tour Sends Strong Scottie Scheffler Message on Saturday originally appeared on Athlon Sports. The PGA Tour celebrated Scottie Scheffler in style on Saturday, honoring the world No. 1 golfer on his birthday with an Instagram post from @pgatour showcasing his top 10 career shots. Advertisement The post, shared earlier today, serves as a tribute to his remarkable journey, timed perfectly as fans and the Tour alike mark his special day. This gesture underscores Scheffler's status as a golfing icon and the Tour's commitment to celebrating its brightest stars. The post highlights iconic moments, including his hole-in-one at the 2023 Charles Schwab Challenge and his remarkable eagle hole-out at the 2024 Players Championship. These shots reflect the precision and power that have defined his rise, with three wins in his last five starts this season, including a victory at the 2025 PGA Championship. Scottie Scheffler plays his shot from the tenth tee during the first round.© Charles LeClaire-Imagn Images The birthday tribute aligns with Scheffler being in contention at the Travelers Championship this weekend, tying for the 36-hole lead with a score of nine under par. Advertisement This celebration sends a clear message: Scheffler, at 29, is the Tour's present and future and will continue to dominate a majority of the tournaments he plays in. With competitors like Tommy Fleetwood and Justin Thomas challenging his lead, his career highlights remind fans of his consistency and clutch performances. The post has sparked excitement, reinforcing the Tour's intent to honor excellence while hyping its toughest course setups and merit-based finales. For golf enthusiasts, it's a fitting birthday salute to a player redefining the sport. Related: PGA Tour Teases Scottie Scheffler, Justin Thomas Pairing at Travelers Championship This story was originally reported by Athlon Sports on Jun 21, 2025, where it first appeared.
